The ARHGAP18 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, engineered to disrupt the ARHGAP18 gene. This product provides a heterogeneous pool of cells harboring loss-of-function mutations at the target locus, enabling robust functional studies of ARHGAP18 without the limitations of single-cell-derived clonal lines. The polyclonal format preserves a broad genetic background while ensuring consistent ARHGAP18 ablation across the population, making it suitable for high-throughput screening and pooled analysis.
The A-549 host cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male and is widely recognized as a model of human alveolar type II pulmonary epithelium. These adherent epithelial cells are extensively utilized in cancer biology to study lung adenocarcinoma pathogenesis, drug metabolism, and respiratory infection. Their well-characterized genomic and phenotypic properties provide a reliable platform for investigating gene function in a disease-relevant context.
ARHGAP18 encodes a Rho GTPase-activating protein that specifically stimulates the intrinsic GTP hydrolysis of RhoA, converting active RhoA-GTP to inactive RhoA-GDP. By inactivating RhoA, ARHGAP18 negatively regulates downstream effectors such as Rho-associated coiled-coil kinase (ROCK) and myosin light chain (MLC) phosphorylation, leading to decreased actin stress fiber formation and enhanced cell-cell adhesion. This activity promotes actin cytoskeleton remodeling and endothelial barrier integrity. Upstream, ARHGAP18 is transcriptionally regulated by Kr??ppel-like factors KLF2 and KLF4, and is activated in response to shear stress and VEGF signaling. ARHGAP18 interacts directly with RhoA and indirectly with focal adhesion proteins and actin cytoskeleton components, positioning it as a central node in Rho GTPase signaling and focal adhesion dynamics.
In A-549 lung adenocarcinoma cells, knockout of ARHGAP18 disrupts its normal braking function on RhoA, resulting in hyperactivation of RhoA/ROCK/MLC signaling. This leads to increased actin stress fiber assembly, enhanced focal adhesion turnover, and elevated cell migration and invasion??phenotypes closely associated with metastatic progression. Consequently, this knockout model is particularly valuable for dissecting the molecular mechanisms of Rho-driven lung cancer metastasis and for evaluating the role of Rho GTPase signaling in epithelial barrier function. It also offers a relevant system to study the interplay between ARHGAP18 loss and angiogenesis in the tumor microenvironment.
Researchers can apply the ARHGAP18 Knockout A-549 Polyclonal Cells in a variety of experimental contexts, including transwell migration and invasion assays to quantify metastatic behavior, RhoA activity assays such as G-LISA to monitor GTP-bound RhoA levels, and phalloidin staining to visualize actin cytoskeleton rearrangements. Complementary analysis by Western blotting or RT-qPCR enables confirmation of ARHGAP18 disruption, while immunofluorescence for focal adhesion proteins assesses adhesion complex integrity. This model supports investigations in lung adenocarcinoma biology, anti-angiogenic therapy development, and Rho pathway-targeted drug discovery. For further information or to inquire about ordering, please contact Ascent Research.
